GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SK Biopharmaceuticals Co 326030.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

86,700

-2.36%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SK Biopharmaceuticals Co

Its shares trade on KRX under the ticker 326030.KS. It has been listed since 2 July 2020. In the fiscal year to 31 December 2025, it reported revenue of ₩706.74bn and net income of ₩266.95bn. At that date it held total assets of ₩1.20trn and shareholders' equity of ₩813.04bn.

SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2020-07-02. The firm mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The firm also engages in the new drug development business.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
2 Jul 2020
Website
skbp.com ↗

Leadership

Pay as last reported

  • Mr. Dong Hun LeeChief Executive Officer, Director₩1.28bn
  • Mr. Ji Yeong JungDirector
  • Mr. Yeon Tae KimOther Non-Executive Director
  • Ms. Gyeong Seon ChoNon-Executive Independent Director
  • Mr. Min Ji KimNon-Executive Independent Director
  • Mr. Yong Jin KimNon-Executive Independent Director
  • Ms. Ji Hui SeoNon-Executive Independent Director
  • Mr. Hyeong Rae ChoIR Contact Officer, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
88
Environment
99
Social
99
Governance
66
Direct emissions (scope 1)
433 t
Energy emissions (scope 2)
1,046 t
Value chain emissions (scope 3)
11,882 t
Women in the workforce
48.3871%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • SK Biopharmaceuticals Co Ltd benefits from several strengths that position it well in the market. These include:

Weaknesses

  • Despite its strengths, SK Biopharmaceuticals Co Ltd also faces certain weaknesses that could hinder its growth and success. These include:

Opportunities

  • SK Biopharmaceuticals Co Ltd can leverage various opportunities to further enhance its market position and growth prospects:

Threats

  • SK Biopharmaceuticals Co Ltd faces certain threats that could impact its market position and profitability:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.